July 15, 2016 10:52 AM EDT

Ziopharm craters on report of patient death in gene therapy study

Arsalan Arif

Founder

Shares of Ziopharm $ZIOP plunged this morning after Adam Feuerstein at TheStreet broke the story that one patient in its gene therapy study dubbed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ziopharm craters on report of patient death in gene therapy study

Arsalan Arif

Founder

Sign up to read this article for free.

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat

Zio­pharm craters on re­port of pa­tient death in gene ther­a­py study

Arsalan Arif

Founder

Sign up to read this article for free.

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Ziopharm craters on report of patient death in gene therapy study

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat